ClinicalTrials.gg
Active, not recruitingNCT05120830NTLA-2002Updated Sep 25, 2026

NTLA-2002 in Adults With Hereditary Angioedema (HAE)

A Phase 1/2 interventional study of Biological NTLA-2002 and Normal Saline IV Administration in Hereditary Angioedema, sponsored by Intellia Therapeutics. Active, not recruiting at 9 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Intellia Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

Updated Sep 25, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Angioedemas, Hereditary with a site in France — 8 open to participants now, 13 under way, 11 of them phase 3. Angioedemas, Hereditary · France.

Enrollment
24th of 28
37 · median 103
Started
2021
with 5 others
Phase 1/2
Only one
of the 38
Primary completion
2024-04
later than 0 of 12 live
Registered
17th of 38
by date
Lead sponsor
3 of 38
Intellia Therapeutics

Among the 38 studies in Angioedemas, Hereditary with a site in France, this one is the 24th largest by enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2021, is the only one in phase 1/2, reaches primary completion later than 0 of the 12 other live ones, and was the 17th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

8 of the 38 studies in Angioedemas, Hereditary with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Angioedemas, Hereditary with a site in France, or all of them as a file.
02

Study summary

This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).

03

Conditions studied

  • Hereditary Angioedema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18 years
  2. Diagnosis of HAE Types I or II
  3. Ability to provide evidence of HAE attacks to meet the screening requirement
  4. Subjects must have access to, and the ability to use, ≥ 1 acute medication(s) to treat angioedema attacks.
  5. Adequate chemistry and hematology measures at screening
  6. Subjects must agree not to participate in another interventional study for the duration of this trial.
  7. Subjects must be capable of providing signed

Exclusion criteria

Exclusion Criteria:

  1. Concurrent diagnosis of any other type of recurrent angioedema
  2. Subjects who have known negative reaction or to any lipid nanoparticles (LNP) component.
  3. Any condition that, in the Investigator's opinion, could adversely affect the safety of the subject.
  4. Unwilling to comply with study procedures.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Phase 1 Study Arm

    Participants assigned to 1 of 3 dose-escalation cohorts will receive a single dose of NTLA-2002 on Day 1 and will then be followed for 104 weeks. Primary observation period is 16 weeks.

    Biological: Biological NTLA-2002

  • Experimental
    Phase 2 Experimental Study Arm

    Participants randomized to NTLA-2002 (2 dose levels), will receive a single dose of NTLA-2002 on Day 1 and will then be followed for 104 weeks. Primary observation period is 16 weeks.

    Biological: Biological NTLA-2002

  • Placebo comparator
    Phase 2 Placebo Comparator Study Arm

    Participants randomized to placebo will receive IV normal saline on Day 1 and will then be followed for up to 104 weeks. Primary observation period is 16 weeks.

    Other: Normal Saline IV Administration

  • Experimental
    Placebo Crossover and Follow-On Dosing Substudy Arm

    Participants assigned to this Substudy Arm (participants who previously received either 25mg or placebo only) will have the opportunity to receive a single dose of NTLA-2002 (50mg) and will then be followed for 52 weeks.

    Biological: Biological NTLA-2002

Interventions

  • BiologicalBiological NTLA-2002

    CRISPR/Cas9 gene editing system delivered by LNP for IV administration

  • OtherNormal Saline IV Administration

    The administration of IV normal saline

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of NTLA-2002 as determined by adverse events (AEs) and dose limiting toxicities (DLTs)

    (Phase 1 only)

    Time frame: From NTLA-2002 infusion up to week 104 post-infusion

  2. Number of HAE attacks per month (Weeks 1-16)

    (Phase 2 only)

    Time frame: From study drug infusion up to week 16 post-infusion

Secondary outcomes

  1. Change from baseline in total plasma kallikrein protein level

    (Phase 1 \& 2)

    Time frame: From NTLA-2002 infusion up to week 104 post-infusion

  2. Plasma and urine concentrations for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA

    (Phase 1 \& 2)

    Time frame: From NTLA-2002 infusion up to week 104 post-infusion

  3. Safety and tolerability of NTLA-2002 as determined by AEs

    (Phase 2 only)

    Time frame: From study drug infusion up to week 104 post-infusion

  4. Number of HAE attacks per month (Weeks 5-16)

    (Phase 2 only)

    Time frame: From week 6 post-infusion up to week 16 post-infusion

  5. Number of HAE attacks per month requiring acute therapy (Weeks 1-16, Weeks 5-16)

    (Phase 2 only)

    Time frame: From study drug infusion up to week 16 post-infusion

07

Study locations

9 sites
  • Clinical Trial Site
    Campbelltown, Australia
  • Clinical Trial Site
    Grenoble, France
  • Clinical Trial Site
    Lille, France
  • Clinical Trial Site
    Paris, France
  • Clinical Trial Site
    Berlin, Germany
  • Clinical Trial Site
    Frankfurt, Germany
  • Clinical Trial Site
    Amsterdam, Netherlands
  • Clinical Trial Site
    Auckland, New Zealand
  • Clinical Trial Site
    Cambridge, United Kingdom
08

References and documents

Publications

  • Cohn DM, Gurugama P, Magerl M, Katelaris CH, Launay D, Bouillet L, Petersen RS, Lindsay K, Aygoren-Pursun E, Maag D, Butler JS, Shah MY, Golden A, Xu Y, Abdelhady AM, Lebwohl D, Longhurst HJ. CRISPR-Based Therapy for Hereditary Angioedema. N Engl J Med. 2025 Jan 30;392(5):458-467. doi: 10.1056/NEJMoa2405734. Epub 2024 Oct 24. PubMed 39445704 ↗
  • Longhurst HJ, Lindsay K, Petersen RS, Fijen LM, Gurugama P, Maag D, Butler JS, Shah MY, Golden A, Xu Y, Boiselle C, Vogel JD, Abdelhady AM, Maitland ML, McKee MD, Seitzer J, Han BW, Soukamneuth S, Leonard J, Sepp-Lorenzino L, Clark ED, Lebwohl D, Cohn DM. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. N Engl J Med. 2024 Feb 1;390(5):432-441. doi: 10.1056/NEJMoa2309149. PubMed 38294975 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2021 to primary completion in Apr 2024, 27 months.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → May 2027, on Sep 25, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2021
First posted
Nov 15, 2021
StartActual
Dec 10, 2021
Primary completionActual
Apr 4, 2024
CompletionEst.
May 31, 2027was Jul 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Jul 2026→May 31, 2027
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Study completion Jul 2026→May 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05120830
Lead sponsor
Intellia Therapeutics
Responsible party
Sponsor
First posted
Nov 15, 2021
Start date
Dec 10, 2021
Primary completion
Apr 4, 2024
Completion
May 31, 2027 (estimated)
Last update
Sep 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion